Kodiak Sciences has reported positive interim findings from an ongoing Phase Ib clinical trial of its anti-VEGF antibody biopolymer conjugate, KSI-301, for the treatment of three eye disorders.

KSI-301 is an investigational product intended to provide first-line therapy for retinal vascular diseases. It has been formulated for intravitreal administration.

In the Phase Ib study, the company enrolled patients with wet age-related macular degeneration (AMD), diabetic macular oedema (DME), and macular oedema caused by retinal vein occlusion (RVO).

Participants received three monthly doses of 2.5mg or 5mg KSI-301 and were monitored for the following seven months. They also had additional treatments based on protocol-specified criteria.

Data from 35 patients showed improvements in vision and retinal anatomy over 12 weeks.

Kodiak said that vision was measured as the change in best-corrected visual acuity (BCVA) on a standardised eye chart, with retinal anatomy measurement being the change in retinal central subfield thickness (CST).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As of the data cut-off date, the Phase Ib trial recruited 77 patients who were exposed to multiple doses of KSI-301. The therapeutic was well-tolerated, without any drug-related adverse events or serious adverse events.

According to the results, most of the adverse events observed during the study were mild and consistent with those associated with intravitreally-injected anti-VEGF agents.

Based on these positive findings, the company is planning to expand the study with additional cohorts.

Kodiak Sciences chief medical officer and chief development officer Jason Ehrlich said: “In addition to vision and anatomic improvements, we have observed encouraging signs of disease modification. These findings increase our conviction in the promise of KSI-301 and the further potential of our ABC Platform.”

The company intends to start patient enrolment in a head-to-head Phase II trial of KSI-301 for treatment-naïve wet AMD patients in the third quarter of this year.